Beigi Richard H, Fortner Kimberly B, Munoz Flor M, Roberts Jeff, Gordon Jennifer L, Han Htay Htay, Glenn Greg, Dormitzer Philip R, Gu Xing Xing, Read Jennifer S, Edwards Kathryn, Patel Shital M, Swamy Geeta K
Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pennsylvania.
Department of Obstetrics and Gynecology, Vanderbilt University, Nashville, Tennessee Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University, Nashville, Tennessee.
Clin Infect Dis. 2014 Dec 15;59 Suppl 7(Suppl 7):S408-14. doi: 10.1093/cid/ciu708.
Maternal immunization is an effective strategy to prevent and/or minimize the severity of infectious diseases in pregnant women and their infants. Based on the success of vaccination programs to prevent maternal and neonatal tetanus, maternal immunization has been well received in the United States and globally as a promising strategy for the prevention of other vaccine-preventable diseases that threaten pregnant women and infants, such as influenza and pertussis. Given the promise for reducing the burden of infectious conditions of perinatal significance through the development of vaccines against relevant pathogens, the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) sponsored a series of meetings to foster progress toward clinical development of vaccines for use in pregnancy. A multidisciplinary group of stakeholders convened at the NIH in December 2013 to identify potential barriers and opportunities for scientific advancement in maternal immunization.
孕产妇免疫接种是预防和/或减轻孕妇及其婴儿传染病严重程度的有效策略。基于预防孕产妇和新生儿破伤风疫苗接种计划的成功,孕产妇免疫接种在美国和全球都受到了广泛欢迎,成为预防其他威胁孕妇和婴儿的疫苗可预防疾病(如流感和百日咳)的一项有前景的策略。鉴于通过研发针对相关病原体的疫苗有望减轻具有围产期意义的传染病负担,美国国立卫生研究院(NIH)下属的国家过敏和传染病研究所微生物学和传染病司主办了一系列会议,以推动用于孕期的疫苗的临床开发取得进展。2013年12月,一个多学科利益相关者小组在NIH召开会议,确定孕产妇免疫接种科学进步的潜在障碍和机遇。